Search

everythinglearnresearchcommunity

for

Search:↓

Low-dose oral isotretinoin improved hair loss and facial bumps in patients with a specific type of hair loss.

The mTOR pathway proteins are altered in the hair follicles of patients with Lichen Planopilaris and Frontal Fibrosing Alopecia.

Low-dose naltrexone may help reduce redness in certain scalp conditions.

Frontal fibrosing alopecia can sometimes look like syphilitic hair loss.

Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.

Frontal fibrosing alopecia is a hair loss condition in postmenopausal women, similar to lichen planopilaris, with ineffective treatments.

The study found that Frontal Fibrosing Alopecia affects a broader age range of women and early treatment can help stop hair loss.

Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.

No treatment has been proven to effectively stop hair loss or regrow hair in Frontal Fibrosing Alopecia, and more research is needed.

Some treatments can stabilize Frontal Fibrosing Alopecia, but more research is needed to find effective treatments, and hair transplants often fail.

Inflammation around hair follicles may worsen hair loss; evaluating and treating it can improve transplant results.

Plasma Rich in Growth Factors may help reduce hair loss in Frontal Fibrosing Alopecia.

Frontal fibrosing alopecia is linked to hypothyroidism but doesn't affect quality of life.

Most patients with frontal fibrosing alopecia are middle-aged women, often have thyroid disease, and some treatments can help stabilize the condition.

Frontal Fibrosing Alopecia is a type of hair loss affecting mostly older women, with no agreed best treatment.

Frontal fibrosing alopecia and ulerythema ophryogenes may be related and can evolve from one to the other.

The cause of Frontal Fibrosing Alopecia is unclear, diagnosis involves clinical evaluation and various treatments exist, but their effectiveness is uncertain.

A young man was initially misdiagnosed with a scalp condition but was found to have a fungal infection, which improved with antifungal treatment.

Some women with Frontal Fibrosing Alopecia also have Lichen Planopilaris, which can lead to more symptoms and affect hair outside the scalp.

Lower PPARγ levels and specific gene variations are linked to more severe Frontal Fibrosing Alopecia.

Some patients developed skin inflammation after obesity surgery, and a medication called dapsone helped treat it.

Combination therapy with steroids and pimecrolimus improved or stabilized hair loss in most patients with Frontal Fibrosing Alopecia, who also had a high rate of hypothyroidism.

Early diagnosis and combination therapy, especially with finasteride and dutasteride, are key to managing Frontal Fibrosing Alopecia effectively.

A woman with frontal fibrosing alopecia experienced unusual hair growth after using a specific topical lotion.

Two trichoscopic patterns found in hair loss: diffuse fibrotic and androgenetic alopecia, affecting treatment choice and regrowth chances.

A young man with an unusual type of scarring hair loss suggests a possible new variant of a known scalp condition.

A genetic marker linked to a type of hair loss was found in most patients studied.

Antimalarial agents are effective for LPP, and intralesional steroids are effective for FFA.

The current understanding of frontal fibrosing alopecia involves immune, genetic, hormonal factors, and possibly environmental triggers, but more research is needed for effective treatments.

Frontal fibrosing alopecia and androgenetic alopecia may be related, with a possible shared cause.